Braveheart Bio, Inc. 8K

Braveheart Bio reported Q2 2026 results, initiated a Phase 3 oHCM trial for BHB-1893, and significantly strengthened its balance sheet via Series A financing and an August 2026 IPO expected to fund operations into 2029.

Braveheart Bio, Inc. reported its unaudited second quarter 2026 financial results and provided a business update, highlighting the initiation of the Phase 3 LIONHEART-HCM trial of its lead candidate BHB-1893 in obstructive hypertrophic cardiomyopathy, strong Phase 2 data in non-obstructive HCM supporting a planned global Phase 3 NOBLEHEART-HCM trial in 2027, completion of a $60 million Series A preferred stock financing in April 2026, and an August 2026 initial public offering on Nasdaq that raised approximately $404.5 million in net proceeds, resulting in a pro forma cash balance of about $527.3 million expected to fund operations into 2029, alongside reporting a Q2 2026 net loss of $15.0 million driven by increased R&D and G&A expenses as the company scales as a newly public clinical-stage biopharmaceutical company.

Filing Facts

CIK

2131524

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-060904

Alert Tier

7